Patients with hemodialysis (HD) are known to have carnitine deficiency ([@B1]). This may contribute to clinical disorders, including cachexia, dyslipidemia, erythropoiesis stimulating agent-resistant anemia, insulin resistance and glucose intolerance, muscle weakness, and myopathy as well as to intradialytic symptoms such as muscle cramps, hypotension, and cardiac arrhythmia. Free carnitine levels decrease principally as a result of dialytic loss, whereas decreased renal clearance and impaired β-oxidation of fatty acids lead to the accumulation of acylcarnitine and an abnormally high ratio of plasma acylcarnitine to free carnitine ([@B1]).

We previously reported that anemia, atherosclerosis, and the cardiac activity were improved by oral levocarnitine therapy while anemia was improved by intravenous levocarnitine therapy in HD patients ([@B2], [@B3]). Kaneko et al. reported that levocarnitine therapy improved cardiac dysfunction via the amelioration of the abnormal myocardial fatty acid metabolism ([@B4]). Echocardiographic measurements of the cardiac activity have been performed on dialysis patients to study the effect of chronic oral supplementation of levocarnitine; the results showed a statistically significant improvement in the systolic and diastolic function of the left ventricle ([@B5]). Sakurabayashi et al. reported that the myocardial washout of ^123^I labeled β-methyl-*p*-iodophenyl-pentadecanoic acid (BMIPP), a fatty acid analogue used to examine myocardial metabolism, decreased in patients on long-term HD and was restored by levocarnitine therapy ([@B6]). The washout of BMIPP from the heart also decreases after the disturbance of mitochondrial carnitine acyltransferase 1 by tetradecylglycidic acid administration ([@B6], [@B7]). These results suggest that, in patients undergoing HD, carnitine deficiency disturbs myocardial fatty acid metabolism and may induce myocardial lipid accumulation. A decreased free carnitine concentration results in disturbed fatty acid transport into mitochondria; subsequently, the mitochondrial accumulation of acylcarnitine perturbs key enzymes of energy production and ATP transport. Therefore, ameliorating the myocardial fatty acid metabolism and acyl/free carnitine ratio due to levocarnitine treatment might help improve the left ventricular ejection fraction (LVEF) and reduce the left ventricular mass index (LVMI).

Cardiac disease is a major problem among dialysis patients, accounting for approximately half of all deaths in this patient population. Several studies have investigated the effect of levocarnitine administration on the cardiac function, with the findings summarized in the included [Table](#t001){ref-type="table"} ([@B3], [@B6], [@B8]-[@B17]). A significant correlation between the LVEF and endogenous levocarnitine levels has been reported, with these patients exhibiting considerable improvement in the LVEF after administration of levocarnitine for three months, a result that was particularly pronounced in patients experiencing recurrent hypotensive episodes ([@B11]).

###### 

Studies of the Effect of Levocarnitine on the Cardiac Function and Hypotension in Dialysis Patients.

  Reference               Study design                                      Population       Dose and route                                      Treatment duration   Findings
  ----------------------- ------------------------------------------------- ---------------- --------------------------------------------------- -------------------- ---------------------------------------
  8                       Two-way, crossover, double-blind                  9 HD patients    990 mg/day PO followed by placebo for 2 mo each     2 mo                 ↓Hypotension
  9 HD patients           Placebo followed by 990 mg/day PO for 2 mo each                                                                                             
  9                       Two-way, parallel, double-blind                   14 HD patients   2 g/Dx, IV                                          6 weeks              No difference in the cardiac function
  14 HD patients          Placebo                                                                                                                                     
  10                      Two-way, parallel, double-blind                   38 HD patients   20 mg/kg per Dx, IV                                 6 mo                 ↓Hypotension
  44 HD patients          Placebo                                                                                                                                     
  11                      One-way, open-label                               13 HD patients   1 g/Dx, IV                                          3 mo                 ↑LVEF T~0~: 42.4% T~3~: 48.6%
  12                      Two-way, parallel, open-label                     25 HD patients   1 g/Dx, IV and 1 g/non-Dx PO                        36 mo                ↑LVEF
  35 HD patients          No treatment                                      ↓LVEDV                                                                                    
  6                       One-way, open-label                               11 HD patients   1 g/day PO followed by 0.5 g/day PO for 1 mo each   2 mo                 ↔ LVEDD, LVFS
  ↑Cardiac scintigraphy                                                                                                                                               
  13                      One-way, open-label                               9 HD patients    500 mg/day, PO                                      6 mo                 ↑LVEF T~0~: 44.9% T~6~: 53.8%
  (impaired LVEF)         ↓CTR                                                                                                                                        
  14                      One-way, open-label                               11 HD patients   1 g/Dx, IV                                          8 mo                 ↑LVEF T~0~: 32.0% T~8~: 41.8%
  15                      Two-way, parallel, open-label                     10 HD patients   10 mg/kg/day, PO                                    12 mo                ↓LVMI
  10 HD patients          No treatment                                                                                                                                
  16                      Two-way, parallel, double-blind                   20 HD patients   1,500 mg/day, PO                                    6 mo                 No difference in the cardiac function
  35 HD patients          No treatment                                                                                                                                
  17                      Two-way, parallel, double-blind                   10 HD patients   900 mg/day, PO                                      3 mo                 ↑LVEF T~0~: 61.8% T~3~: 64.4%
  8 HD patients           Placebo                                           ↓Hypotension                                                                              
  3                       Two-way, parallel, open-label                     75 HD patients   20 mg/kg/day, PO                                    12 mo                ↑LVEF T~0~: 53.1% T~12~: 58.6%
  73 HD patients          No treatment                                      ↓LVMI                                                                                     

CTR: cardiothoracic ratio, Dx: dialysis session, HD: hemodialysis, IV: intravenous injection, LVEDD: left ventricular end-diastolic dimension, LVEDV: left ventricular end-diastolic volume, LVFS: left ventricular fractional shortening, LVEF: left ventricular ejection fraction, LVMI: left ventricular mass index, mo: months, PO: per os (orally), T: treatment duration

Although mounting evidence supports the role of levocarnitine in the treatment of left ventricular dysfunction, other studies have obtained negative results ([@B6], [@B9]); however, the results of these studies should be interpreted with caution, as the patients in these studies had a normal baseline LVEF. We previously reported that the LVMI was an independent predictor of improvement in the LVEF following levocarnitine therapy. Furthermore, the responders to levocarnitine treatment were patients with left ventricular hypertrophy (LVH), as defined by the LVMI ([@B3]). Therefore, levocarnitine therapy is useful for hemodialysis patients with LVH; these patients may benefit from such therapy, with amelioration of the cardiac function and mitigation of the LVMI. The findings of these studies indicate that levocarnitine has great potential utility in the treatment of cardiac dysfunction, particularly in patients with LVH and dialysis-related hypotension.

Carnitine metabolism is an essential metabolite involved in fatty acid metabolism and the regulation of carbohydrate metabolism. However, this activity is altered during uremia. The combination of uremia-induced LVH and carnitine deficiency contributes to the altered myocardial metabolism and impaired cardiac function. Levocarnitine treatment may partially ameliorate this uremic hypertrophy as well as exert beneficial effects on metabolism. Further large-scale clinical studies are necessary to ascertain whether or not this therapy has a significant effect on reducing the rates of cardiac mortality and morbidity.
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